An egfr-mutated lung adenocarcinoma undergoing squamous cell carcinoma transformation exhibited a durable response to afatinib

Mitsuo Sato; Akira Matsui; Yoshie Shimoyama; Norihito Omote; Masahiro Morise; Tetsunari Hase; Ichidai Tanaka; Kojiro Suzuki; Yoshinori Hasegawa

doi:10.2169/internalmedicine.0999-18

An egfr-mutated lung adenocarcinoma undergoing squamous cell carcinoma transformation exhibited a durable response to afatinib

Mitsuo Sato
, Akira Matsui
, Yoshie Shimoyama
, Norihito Omote
, Masahiro Morise
, Tetsunari Hase
, Ichidai Tanaka
, Kojiro Suzuki
, Yoshinori Hasegawa

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second-or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.

Original language	English
Pages (from-to)	3429-3432
Number of pages	4
Journal	Internal Medicine
Volume	57
Issue number	23
DOIs	https://doi.org/10.2169/internalmedicine.0999-18
Publication status	Published - 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Internal Medicine

Access to Document

10.2169/internalmedicine.0999-18

Cite this

@article{105421fb23f14a2383939b27cccc03a2,

title = "An egfr-mutated lung adenocarcinoma undergoing squamous cell carcinoma transformation exhibited a durable response to afatinib",

abstract = "Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second-or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.",

keywords = "Afatinib, EGFR mutation, Erlotinib, Squamous cell carcinoma transformation",

author = "Mitsuo Sato and Akira Matsui and Yoshie Shimoyama and Norihito Omote and Masahiro Morise and Tetsunari Hase and Ichidai Tanaka and Kojiro Suzuki and Yoshinori Hasegawa",

year = "2018",

doi = "10.2169/internalmedicine.0999-18",

language = "English",

volume = "57",

pages = "3429--3432",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "23",

}

TY - JOUR

T1 - An egfr-mutated lung adenocarcinoma undergoing squamous cell carcinoma transformation exhibited a durable response to afatinib

AU - Sato, Mitsuo

AU - Matsui, Akira

AU - Shimoyama, Yoshie

AU - Omote, Norihito

AU - Morise, Masahiro

AU - Hase, Tetsunari

AU - Tanaka, Ichidai

AU - Suzuki, Kojiro

AU - Hasegawa, Yoshinori

PY - 2018

Y1 - 2018

N2 - Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second-or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.

AB - Squamous cell carcinoma (SCC) transformation has been identified as a mechanism of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib or erlotinib, in EGFR-mutated lung cancer. However, whether second-or third-generation TKIs can overcome resistance due to SCC transformation remains unclear. We herein report an EGFR-mutated lung adenocarcinoma undergoing transformation into SCC that exhibited a durable response to afatinib, which is a second-generation irreversible EGFR-TKI. We suggest that afatinib can be considered as a treatment option for EGFR-mutated tumor undergoing SCC transformation, particularly in the absence of a T790M mutation.

KW - Afatinib

KW - EGFR mutation

KW - Erlotinib

KW - Squamous cell carcinoma transformation

UR - https://www.scopus.com/pages/publications/85057980631

UR - https://www.scopus.com/pages/publications/85057980631#tab=citedBy

U2 - 10.2169/internalmedicine.0999-18

DO - 10.2169/internalmedicine.0999-18

M3 - Article

C2 - 30101911

AN - SCOPUS:85057980631

SN - 0918-2918

VL - 57

SP - 3429

EP - 3432

JO - Internal Medicine

JF - Internal Medicine

IS - 23

ER -

An egfr-mutated lung adenocarcinoma undergoing squamous cell carcinoma transformation exhibited a durable response to afatinib

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this